Stockscreener 앱 받기
6.91
1.57%
-0.11
Entrada Therapeutics Inc 주식(TRDA)의 최신 뉴스
(TRDA) Long Term Investment Analysis - news.stocktradersdaily.com
Harbor Capital Advisors Inc. Makes New Investment in Entrada Therapeutics, Inc. (NASDAQ:TRDA) - Defense World
Wall Street Zen Downgrades Entrada Therapeutics (NASDAQ:TRDA) to Sell - Defense World
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Acquires 21,594 Shares of Entrada Therapeutics, Inc. (NASDAQ:TRDA) - Defense World
Millennium Management LLC Sells 98,416 Shares of Entrada Therapeutics, Inc. (NASDAQ:TRDA) - Defense World
Entrada Therapeutics Holds Virtual Annual Stockholders Meeting - TipRanks
Entrada Therapeutics, Inc. (NASDAQ:TRDA) Holdings Raised by Bank of America Corp DE - Defense World
Transcript : Entrada Therapeutics, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-09-2025 08 - MarketScreener
Mackenzie Financial Corp Makes New Investment in Entrada Therapeutics, Inc. (NASDAQ:TRDA) - Defense World
How the (TRDA) price action is used to our Advantage - news.stocktradersdaily.com
Entrada Therapeutics, Inc. (NASDAQ:TRDA) Stock Position Trimmed by Nuveen Asset Management LLC - Defense World
Entrada Therapeutics expands board with new director By Investing.com - Investing.com South Africa
Entrada Therapeutics Appoints Maha Radhakrishnan, M.D., to its Board of Directors - GlobeNewswire
Entrada Therapeutics expands board with new director - Investing.com
Entrada Therapeutics (TRDA) Welcomes New Board Member | TRDA Stock News - GuruFocus
Entrada Therapeutics Appoints New Board Member - TipRanks
3,324 Shares in Entrada Therapeutics, Inc. (NASDAQ:TRDA) Bought by BNP Paribas Financial Markets - Defense World
Ameriprise Financial Inc. Buys 2,517 Shares of Entrada Therapeutics, Inc. (NASDAQ:TRDA) - Defense World
Buy Rating for Entrada Therapeutics: Strategic Positioning and Regulatory Advances in Exon-Skipping Therapeutics - TipRanks
Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule - MarketScreener
Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Entrada Therapeutics Awards Nearly 24,000 RSUs in Latest Employee Compensation Plan - Stock Titan
Deutsche Bank AG Grows Stock Holdings in Entrada Therapeutics, Inc. (NASDAQ:TRDA) - Defense World
Entrada Therapeutics to start DMD trial in Q3 2025 By Investing.com - Investing.com South Africa
Entrada Therapeutics (TRDA) Gains EU Approval for Advanced Clinical Study | TRDA Stock News - GuruFocus
Entrada Therapeutics to start DMD trial in Q3 2025 - Investing.com
Entrada Therapeutics Receives EU Authorization to Proceed with ELEVATE-45-201 Clinical Study for Duchenne Muscular Dystrophy, Set to Begin in Q3 2025 - Nasdaq
Breakthrough DMD Treatment Gets EU Green Light: Entrada's Novel Exon 45 Therapy Heads to Clinical Trials - Stock Titan
HC Wainwright Brokers Boost Earnings Estimates for TRDA - Defense World
Layoff Tracker: Boundless Laying Off 33% of Staff - BioSpace
Q2 Earnings Forecast for TRDA Issued By HC Wainwright - Defense World
HC Wainwright Reiterates Buy Rating for Entrada Therapeutics (NASDAQ:TRDA) - Defense World
Northern Trust Corp Has $5.50 Million Holdings in Entrada Therapeutics, Inc. (NASDAQ:TRDA) - Defense World
Entrada Therapeutics (TRDA) Receives 'Buy' Rating Reiteration by HC Wainwright | TRDA Stock News - GuruFocus
Tower Research Capital LLC TRC Cuts Holdings in Entrada Therapeutics, Inc. (NASDAQ:TRDA) - Defense World
(TRDA) Technical Pivots with Risk Controls - news.stocktradersdaily.com
Roth Capital Issues Negative Outlook for TRDA Earnings - Defense World
Entrada Therapeutics, Inc. (NASDAQ:TRDA) Shares Purchased by Dimensional Fund Advisors LP - Defense World
Entrada Therapeutics price target lowered to $21 from $23 at Roth Capital - TipRanks
Entrada Therapeutics (TRDA) Sees Price Target Adjustment Amid Cl - GuruFocus
Roth Capital Adjusts Price Target for Entrada Therapeutics (TRDA - GuruFocus
Roth Capital Adjusts Price Target for Entrada Therapeutics (TRDA) | TRDA Stock News - GuruFocus
Analysts Are Upgrading Entrada Therapeutics, Inc. (NASDAQ:TRDA) After Its Latest Results - Yahoo Finance
Entrada Therapeutics: Strategic Advancements in DMD Pipeline Drive Buy Rating - TipRanks
Entrada Therapeutics reports Q1 EPS (42c), consensus (77c) - TipRanks
Entrada Therapeutics earnings beat by $0.31, revenue fell short of estimates - Investing.com
Entrada Therapeutics (TRDA) Reports Strong Q1 Revenue and Advances Duchenne Programs | TRDA Stock News - GuruFocus
Entrada Therapeutics, Inc. (TRDA) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance
Entrada Therapeutics Reports First Quarter 2025 Financial Results - The Manila Times
First Trust Advisors LP Sells 7,800 Shares of Entrada Therapeutics, Inc. (NASDAQ:TRDA) - Defense World
MetLife Investment Management LLC Acquires 1,731 Shares of Entrada Therapeutics, Inc. (NASDAQ:TRDA) - Defense World
Wells Fargo & Company MN Buys 3,357 Shares of Entrada Therapeutics, Inc. (NASDAQ:TRDA) - Defense World
Barclays PLC Has $887,000 Holdings in Entrada Therapeutics, Inc. (NASDAQ:TRDA) - Defense World
Analysts Are Bullish on Top Healthcare Stocks: ImmunityBio (IBRX), Axsome Therapeutics (AXSM) - The Globe and Mail
Form 8-KCurrent report - ADVFN
1.11%
1.70%
자본화:
|
볼륨(24시간):